Carborane-Appended Adenine as a Novel Drug Delivery Agent in Boron Neutron Capture Therapy
Advisor(s)
Dr. Narayan S. Hosmane, Northern Illinois University
Location
Room B108-2
Start Date
26-4-2019 10:05 AM
End Date
26-4-2019 10:20 AM
Abstract
Glioblastoma multiforme (GBM) is a highly invasive brain tumor that exhibits a resistance to all the current forms of cancer therapy, therefore making it virtually untreatable and lethal. A potential effective treatment for GBM is boron neutron capture therapy (BNCT), a binary cancer radiation therapy involving the irradiation of 10B-enriched compounds introduced into cancer cells. Unfortunately, BNCT lacks a suitable drug delivery agent. The goal of this research is to synthesize carborane-appended with adenine as an effective drug delivery agent for BNCT. Carborane derivatives have long been considered as an ideal BNCT drug delivery agent due to their high boron content and stability to catabolism. The adenine is utilized as the organic compound to attach to carborane to facilitate the transportation the carborane into the cancer cell. The method involves the synthesis of carborane-appended azide compounds, the alkylation of adenine using propargyl bromide, and the conjugation of the adenine derivative with the polyhedral carborane cage using a click reaction. The synthesis of the carborane-appended adenine is currently being investigated. In the future, the carborane derivatives be purified, isolated, and characterized. The result is the potential candidate for a new and effective drug delivery agent that may be utilized for the treatment of GBM in BNCT applications.
Carborane-Appended Adenine as a Novel Drug Delivery Agent in Boron Neutron Capture Therapy
Room B108-2
Glioblastoma multiforme (GBM) is a highly invasive brain tumor that exhibits a resistance to all the current forms of cancer therapy, therefore making it virtually untreatable and lethal. A potential effective treatment for GBM is boron neutron capture therapy (BNCT), a binary cancer radiation therapy involving the irradiation of 10B-enriched compounds introduced into cancer cells. Unfortunately, BNCT lacks a suitable drug delivery agent. The goal of this research is to synthesize carborane-appended with adenine as an effective drug delivery agent for BNCT. Carborane derivatives have long been considered as an ideal BNCT drug delivery agent due to their high boron content and stability to catabolism. The adenine is utilized as the organic compound to attach to carborane to facilitate the transportation the carborane into the cancer cell. The method involves the synthesis of carborane-appended azide compounds, the alkylation of adenine using propargyl bromide, and the conjugation of the adenine derivative with the polyhedral carborane cage using a click reaction. The synthesis of the carborane-appended adenine is currently being investigated. In the future, the carborane derivatives be purified, isolated, and characterized. The result is the potential candidate for a new and effective drug delivery agent that may be utilized for the treatment of GBM in BNCT applications.